UNCY NASDAQ
Unicycive Therapeutics, Inc.
1W: +2.0%
1M: -23.8%
3M: -27.5%
YTD: -38.3%
1Y: -26.3%
3Y: -59.8%
5Y: -86.6%
$3.61
+0.03 (+0.84%)
After Hours: $3.58 (-0.02, -0.69%)
Weekly Expected Move ±8.7%
$3
$4
$4
$4
$5
Credit Risk of going bust: lower than 61% of companies Debt: 0.7% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the safest four tenths, about 1 in 3,500 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.00 (down 99.9%), Unicycive Therapeutics, Inc. would be worth roughly what it owes.
Total debt $671K against a stock market value of $98.1M.
Distance to default 6.37 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $336K (short-term plus half of long-term), stock volatility 84.6%; Altman Z'' -1.95. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.00 (down 99.9%), Unicycive Therapeutics, Inc. would be worth roughly what it owes.
Total debt $671K against a stock market value of $98.1M.
Distance to default 6.37 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $336K (short-term plus half of long-term), stock volatility 84.6%; Altman Z'' -1.95. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Moderate
50
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$98.1M
52W Range3.35-8.74
Volume1,316,093
Avg Volume1,350,244
Beta1.82
Dividend—
Analyst Ratings
Company Info
CEOShalabh K. Gupta
Employees21
SectorHealthcare
IndustryBiotechnology
IPO Date2021-07-12
Websiteunicycive.com
1975 West El Camino Real
Mountain View, CA 94040
US
Mountain View, CA 94040
US
650 351 4495
About Unicycive Therapeutics, Inc.
Unicycive Therapeutics, Inc. is a U.S.-based biotechnology company dedicated to the creation of innovative treatments for kidney diseases. Its development pipeline includes Renazorb, a therapy for hyperphosphatemia in chronic kidney disease patients, and UNI 494, which is being developed to treat acute kidney injury. Founded in 2016, the firm is headquartered in Los Altos, California.
Latest News
Noble Financial Issues Negative Outlook for UNCY Earnings
Unicycive Therapeutics (UNCY) Loses 21.4% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
UNCY Shareholder Alert: Unicycive Therapeutics, Inc. Securities Class Action Lawsuit - Investors Should Contact SueWallSt
HC Wainwright Issues Optimistic Forecast for UNCY Earnings
ROSEN, NATIONAL TRIAL LAWYERS, Encourages Unicycive Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - UNCY
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Manning Meredith | 0 | — | 2026-10-01 | |
| Kenkare-Mitra Sara | A-Award | 47,941 | — | 2026-05-14 |
| Laumas Sandeep | A-Award | 47,941 | — | 2026-05-14 |
| Gupta Shalabh K. | A-Award | 762,200 | — | 2026-05-14 |
| Kenkare-Mitra Sara | A-Award | 84,200 | — | 2026-05-14 |